XERS Insider Trading Activity and SEC Form 4 Filings
XERS insider trading summary
Over the past 12 months, insiders at Xeris Biopharma Holdings, Inc. (XERS) reported 30 sales worth $5.2M by 7 insiders and no open-market purchases on SEC Form 4. Net insider selling was $5.2M.
Latest XERS insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 2, 2026 | Kevin McCulloch | See Remarks | Sell | $153K (15,000 @ $10.23) |
| Nov 2, 2026 | Steven Pieper | See Remarks | Sell | $51K (5,000 @ $10.23) |
| Nov 2, 2026 | Beth Hecht | See Remarks | Sell | $256K (25,000 @ $10.23) |
| Oct 1, 2026 | Steven Pieper | See Remarks | Sell | $47K (5,000 @ $9.41) |
| Oct 1, 2026 | Beth Hecht | See Remarks | Sell | $157K (16,666 @ $9.41) |
| Oct 1, 2026 | Kevin McCulloch | See Remarks | Sell | $141K (15,000 @ $9.41) |
| Sep 28, 2026 | Kevin McCulloch | See Remarks | Sell | $250K (25,000 @ $10.00) |
| Sep 1, 2026 | Kevin McCulloch | See Remarks | Sell | $127K (15,000 @ $8.49) |
| Sep 1, 2026 | Steven Pieper | See Remarks | Sell | $43K (5,000 @ $8.50) |
| Sep 1, 2026 | Beth Hecht | See Remarks | Sell | $141K (16,666 @ $8.49) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.